Chemoprevention for Bladder Cancer

Journal of Urology

Volumn 176, Issue 5, 2006, Pages 1914-1920

  Busby, J Erik ^a   Kamat, Ashish M ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

bladder; bladder neoplasms; carcinoma; chemoprevention; transitional cell; vitamins

Indexed keywords

ALPHA TOCOPHEROL; ANTIBIOTIC AGENT; ASCORBIC ACID; CEFAZOLIN; CEPHALOSPORIN; CIPROFLOXACIN; COTRIMOXAZOLE; DIALLYL DISULFIDE; EFLORNITHINE; GREEN TEA EXTRACT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISOTHIOCYANIC ACID; ISOTHIOCYANIC ACID DERIVATIVE; LYCOPENE; NITROFURANTOIN; NONSTEROID ANTIINFLAMMATORY AGENT; OLTIPRAZ; PYRIDOXINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RETINOID; SELENIUM;

BLADDER CARCINOMA; BREAST CARCINOMA; CHEMOPROPHYLAXIS; CLINICAL TRIAL; COLON CARCINOMA; EVALUATION; HUMAN; MEDICAL LITERATURE; MEDLINE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CARCINOMA; REVIEW; SOYBEAN; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

HUMANS; URINARY BLADDER NEOPLASMS; VITAMINS;

EID: 33750314830     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2006.07.004     Document Type: Review

References (50)

1. Jemal A., Murray T., Ward E., Samuels A., Tiwari R.C., Ghafoor A., et al. Cancer statistics, 2005. CA Cancer J Clin 55 (2005) 10
2. Lotan R. Retinoids and apoptosis: implications for cancer chemoprevention and therapy. J Natl Cancer Inst 87 (1995) 1655
3. Grubbs C.J., Moon R.C., Squire R.A., Farrow G.M., Stinson S.F., Goodman D.G., et al. 13-Cis-retinoic acid: inhibition of bladder carcinogenesis induced in rats by N-butyl-N-(4-hydroxybutyl)nitrosamine. Science 198 (1977) 743
4. Hicks R.M., Turton J.A., Chowaniec J., Tomlinson C.N., Gwynne J., and Nandra K. Modulation of carcinogenesis in the urinary bladder by retinoids. Ciba Found Symp 113 (1985) 168
5. Castelao J.E., Yuan J.M., Gago-Dominguez M., Skipper P.L., Tannenbaum S.R., Chan K.K., et al. Carotenoids/vitamin C and smoking-related bladder cancer. Int J Cancer 110 (2004) 417
6. Zeegers M.P., Goldbohm R.A., and van den Brandt P.A. Are retinol, vitamin C, vitamin E, folate and carotenoids intake associated with bladder cancer risk?. Results from the Netherlands Cohort Study. Br J Cancer 85 (2001) 977
7. Michaud D.S., Pietinen P., Taylor P.R., Virtanen M., Virtamo J., and Albanes D. Intakes of fruits and vegetables, carotenoids and vitamins A, E, C in relation to the risk of bladder cancer in the ATBC cohort study. Br J Cancer 87 (2002) 960
8. Studer U.E., Jenzer S., Biedermann C., Chollet D., Kraft R., and von Toggenburg H. Adjuvant treatment with a vitamin A analogue (etretinate) after transurethral resection of superficial bladder tumors. Final analysis of a prospective, randomized multicenter trial in Switzerland. Eur Urol 28 (1995) 284
9. Alfthan O., Tarkkanen J., Grohn P., Heinonen E., Pyrhonen S., and Saila K. Tigason (etretinate) in prevention of recurrence of superficial bladder tumors. A double-blind clinical trial. Eur Urol 9 (1983) 6
10. Decensi A., Torrisi R., Bruno S., Costantini M., Curotto A., Nicolo G., et al. Randomized trial of fenretinide in superficial bladder cancer using DNA flow cytometry as an intermediate end point. Cancer Epidemiol Biomarkers Prev 9 (2000) 1071
11. Lerner S., Sabichi A.L., Grossman H.B., Penson D.F., Dinney C.P.N., and Hemstreet G. Results of a randomized chemoprevention trial with fentretinide in non-muscle invasive bladder cancer. J Urol 173 suppl (2005) 246 abstract 913
12. Yoshida O., Brown R.R., and Bryan G.T. Relationship between tryptophan metabolism and heterotopic recurrences of human urinary bladder tumors. Cancer 25 (1970) 773
13. Byar D., and Blackard C. Comparisons of placebo, pyridoxine, and topical thiotepa in preventing recurrence of stage I bladder cancer. Urology 10 (1977) 556
14. Newling D.W., Robinson M.R., Smith P.H., Byar D., Lockwood R., Stevens I., et al., EORTC Genito-Urinary Tract Cancer Cooperative Group. Tryptophan metabolites, pyridoxine (vitamin B6) and their influence on the recurrence rate of superficial bladder cancer. Results of a prospective, randomised phase III study performed by the EORTC GU Group. Eur Urol 27 (1995) 110
15. Mokhtar N.M., el-Aaser A.A., el-Bolkainy M.N., Ibrahim H.A., el-Din N.B., and Moharram N.Z. Effect of soybean feeding on experimental carcinogenesis-III. Carcinogenecity of nitrite and dibutylamine in mice: a histopathological study. Eur J Cancer Clin Oncol 24 (1988) 403
16. Soloway M.S., Cohen S.M., Dekernion J.B., and Persky L. Failure of ascorbic acid to inhibit FANFT-induced bladder cancer. J Urol 113 (1975) 483
17. Bruemmer B., White E., Vaughan T.L., and Cheney C.L. Nutrient intake in relation to bladder cancer among middle-aged men and women. Am J Epidemiol 144 (1996) 485
18. Jacobs E.J., Henion A.K., Briggs P.J., Connell C.J., McCullough M.L., Jonas C.R., et al. Vitamin C and vitamin E supplement use and bladder cancer mortality in a large cohort of US men and women. Am J Epidemiol 156 (2002) 1002
19. Sigounas G., Anagnostou A., and Steiner M. dl-Alpha-tocopherol induces apoptosis in erythroleukemia, prostate, and breast cancer cells. Nutr Cancer 28 (1997) 30
20. Michaud D.S., Spiegelman D., Clinton S.K., Rimm E.B., Willett W.C., and Giovannucci E. Prospective study of dietary supplements, macronutrients, micronutrients, and risk of bladder cancer in US men. Am J Epidemiol 152 (2000) 1145
21. Lamm D.L., Riggs D.R., Shriver J.S., vanGilder P.F., Rach J.F., and DeHaven J.I. Megadose vitamins in bladder cancer: a double-blind clinical trial. J Urol 151 (1994) 21
22. Nomura A.M., Kolonel L.N., Hankin J.H., and Yoshizawa C.N. Dietary factors in cancer of the lower urinary tract. Int J Cancer 48 (1991) 199
23. Donat S.M., Bayuga S., Herr H.W., and Berwick M. Fluid intake and the risk of tumor recurrence in patients with superficial bladder cancer. J Urol 170 (2003) 1777
24. Michaud D.S., Spiegelman D., Clinton S.K., Rimm E.B., Curhan G.C., Willett W.C., et al. Fluid intake and the risk of bladder cancer in men. N Engl J Med 340 (1999) 1390
25. Jones P.A., and Ross R.K. Prevention of bladder cancer. N Engl J Med 340 (1999) 1424
26. Grubbs C.J., Juliana M.M., Eto I., Casebolt T., Whitaker L.M., Canfield G.J., et al. Chemoprevention by indomethacin of N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder tumors. Anticancer Res 13 (1993) 33
27. Grubbs C.J., Lubet R.A., Koki A.T., Leahy K.M., Masferrer J.L., Steele V.E., et al. Celecoxib inhibits N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder cancers in male B6D2F1 mice and female Fischer-344 rats. Cancer Res 60 (2000) 5599
28. Castelao J.E., Yuan J.M., Gago-Dominguez M., Yu M.C., and Ross R.K. Non-steroidal anti-inflammatory drugs and bladder cancer prevention. Br J Cancer 82 (2000) 1364
29. Blumentals W.A., Foulis P.R., Schwartz S.W., and Mason T.J. Analgesic therapy and the prevention of bladder cancer. Urol Oncol 22 (2004) 11
30. Shariat S.F., Kim J.H., Ayala G.E., Kho K., Wheeler T.M., and Lerner S.P. Cyclooxygenase-2 is highly expressed in carcinoma in situ and T1 transitional cell carcinoma of the bladder. J Urol 169 (2003) 938
31. Messing E.M., Hanson P., and Reznikoff C.A. Normal and malignant human urothelium: in vitro response to blockade of polyamine synthesis and interconversion. Cancer Res 48 (1988) 357
32. Messing E.M., Kim K., Wilding G., Sharkey F., Parnes H., Schultz M., et al. A randomized prospective phase III trial of difluoromethylornithine (DFMO) vs. placebo (P) in preventing recurrence of completely resected low risk superficial bladder cancer. J Urol 173 suppl (2005) 249 abstract 922
33. Okajima E., Tsutsumi M., Ozono S., Akai H., Denda A., Nishino H., et al. Inhibitory effect of tomato juice on rat urinary bladder carcinogenesis after N-butyl-N-(4-hydroxybutyl)nitrosamine initiation. Jpn J Cancer Res 89 (1998) 22
34. Kamat A.M., and Lamm D.L. Antitumor activity of common antibiotics against superficial bladder cancer. Urology 63 (2004) 457
35. Lovisolo J.A., Gianesini G., Maggio M., and Bono A.V. Fluoroquinolone prophylaxis for superficial bladder cancer: results of a randomized study. J Urol 169 suppl (2003) 254 abstract 987
36. Moon R.C., Kelloff G.J., Detrisac C.J., Steele V.E., Thomas C.F., and Sigman C.C. Chemoprevention of OH-BBN-induced bladder cancer in mice by oltipraz, alone and in combination with 4-HPR and DFMO. Anticancer Res 14 (1994) 5
37. Sun C.L., Yuan J.M., Wang X.L., Gao Y.T., Ross R.K., and Yu M.C. Dietary soy and increased risk of bladder cancer: a prospective cohort study of men in Shanghai, China. Int J Cancer 112 (2004) 319
38. Helzlsouer K.J., Comstock G.W., and Morris J.S. Selenium, lycopene, alpha-tocopherol, beta-carotene, retinol, and subsequent bladder cancer. Cancer Res 49 (1989) 6144
39. Riggs D.R., DeHaven J.I., and Lamm D.L. Allium sativum (garlic) treatment for murine transitional cell carcinoma. Cancer 79 (1997) 1987
40. Lau B.H., Woolley J.L., Marsh C.L., Barker G.R., Koobs D.H., and Torrey R.R. Superiority of intralesional immunotherapy with Corynebacterium parvum and Allium sativum in control of murine transitional cell carcinoma. J Urol 136 (1986) 701
41. Marsh C.L., Torrey R.R., Woolley J.L., Barker G.R., and Lau B.H. Superiority of intravesical immunotherapy with Corynebacterium parvum and Allium sativum in control of murine bladder cancer. J Urol 137 (1987) 359
42. Goldbohm R.A., Hertog M.G., Brants H.A., van Poppel G., and van den Brandt P.A. Consumption of black tea and cancer risk: a prospective cohort study. J Natl Cancer Inst 88 (1996) 93
43. Sato D., and Matsushima M. Preventive effects of urinary bladder tumors induced by N-butyl-N-(4-hydroxybutyl)-nitrosamine in rat by green tea leaves. Int J Urol 10 (2003) 160
44. Bianchi G.D., Cerhan J.R., Parker A.S., Putnam S.D., See W.A., Lynch C.F., et al. Tea consumption and risk of bladder and kidney cancers in a population-based case-control study. Am J Epidemiol 151 (2000) 377
45. Lu C.M., Lan S.J., Lee Y.H., Huang J.K., Huang C.H., and Hsieh C.C. Tea consumption: fluid intake and bladder cancer risk in Southern Taiwan. Urology 54 (1999) 823
46. Oh Y.S., Lee H.S., Cho H.J., Lee S.G., Jung K.C., and Park J.H. Conjugated linoleic acid inhibits DNA synthesis and induces apoptosis in TSU-Pr1 human bladder cancer cells. Anticancer Res 23 (2003) 4765
47. Maggiora M., Bologna M., Ceru M.P., Possati L., Angelucci A., Cimini A., et al. An overview of the effect of linoleic and conjugated-linoleic acids on the growth of several human tumor cell lines. Int J Cancer 112 (2004) 909
48. Tang L., and Zhang Y. Dietary isothiocyanates inhibit the growth of human bladder carcinoma cells. J Nutr 134 (2004) 2004
49. Kamat A.M., and Nelkin G.M. Atorvastatin: a potential chemopreventive agent in bladder cancer. Urology 66 (2005) 1209
50. Sylvester R.J., van der Meijden A.P., Witjes J.A., and Kurth K. Bacillus Calmette-Guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials. J Urol 174 (2005) 86